Synta's Ganetespib Granted Fast Track Designation - Quick Facts

(RTTNews) - Synta Pharmaceuticals Corp. (SNTA) announced the U.S. FDA has granted Fast Track designation to the investigation of ganetespib, the company's lead Hsp90 inhibitor drug candidate, to improve overall survival when administered in combination with docetaxel for the treatment of patients with metastatic non-small cell lung adenocarcinoma who have progressed following one prior chemotherapy regimen.

The Fast Track Drug Development Program is designed to facilitate the clinical development and expedite the review of drugs that are intended to treat serious medical conditions and that demonstrate the potential to fill unmet medical needs.